Abstract
The two major neuropathologic hallmarks of Alzheimer's disease are extracellular amyloid β (Aβ) plaques and intracellular neurofibrillary tangles. Several additional pathogenic mechanisms have been described, including inflammation, oxidative damage, ion disregulation and cholesterol metabolism. A number of compounds have been developed, trying to interfere with the above-mentioned mechanisms. These drugs are supposed to modify pathological steps leading to Alzheimer's disease, thus acting on the evolution of the disease. Some of these compounds are under clinical testing, others are in preclinical phases of development. In this review, the main pathogenic steps leading to neurodegeneration will be discussed, together with an update on potentially disease-modifying drugs under testing.
| Original language | English |
|---|---|
| Pages (from-to) | 259-277 |
| Number of pages | 19 |
| Journal | Therapy |
| Volume | 6 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Mar 2009 |
Fingerprint
Keywords
- Alzheimer's disease
- Amyloid
- Anti-inflammatories
- Disease-modifying drugs
- Inflammation
- Tau
ASJC Scopus subject areas
- Medicine(all)
- Pharmacology (medical)
Cite this
Alzheimer's disease : From pathogenesis to novel therapeutic approaches. / Scarpini, Elio; Galimberti, Daniela.
In: Therapy, Vol. 6, No. 2, 03.2009, p. 259-277.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Alzheimer's disease
T2 - From pathogenesis to novel therapeutic approaches
AU - Scarpini, Elio
AU - Galimberti, Daniela
PY - 2009/3
Y1 - 2009/3
N2 - The two major neuropathologic hallmarks of Alzheimer's disease are extracellular amyloid β (Aβ) plaques and intracellular neurofibrillary tangles. Several additional pathogenic mechanisms have been described, including inflammation, oxidative damage, ion disregulation and cholesterol metabolism. A number of compounds have been developed, trying to interfere with the above-mentioned mechanisms. These drugs are supposed to modify pathological steps leading to Alzheimer's disease, thus acting on the evolution of the disease. Some of these compounds are under clinical testing, others are in preclinical phases of development. In this review, the main pathogenic steps leading to neurodegeneration will be discussed, together with an update on potentially disease-modifying drugs under testing.
AB - The two major neuropathologic hallmarks of Alzheimer's disease are extracellular amyloid β (Aβ) plaques and intracellular neurofibrillary tangles. Several additional pathogenic mechanisms have been described, including inflammation, oxidative damage, ion disregulation and cholesterol metabolism. A number of compounds have been developed, trying to interfere with the above-mentioned mechanisms. These drugs are supposed to modify pathological steps leading to Alzheimer's disease, thus acting on the evolution of the disease. Some of these compounds are under clinical testing, others are in preclinical phases of development. In this review, the main pathogenic steps leading to neurodegeneration will be discussed, together with an update on potentially disease-modifying drugs under testing.
KW - Alzheimer's disease
KW - Amyloid
KW - Anti-inflammatories
KW - Disease-modifying drugs
KW - Inflammation
KW - Tau
UR - http://www.scopus.com/inward/record.url?scp=69449086846&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=69449086846&partnerID=8YFLogxK
U2 - 10.2217/14750708.6.2.259
DO - 10.2217/14750708.6.2.259
M3 - Article
AN - SCOPUS:69449086846
VL - 6
SP - 259
EP - 277
JO - Therapy
JF - Therapy
SN - 1475-0708
IS - 2
ER -